"We are now starting to establish GMP facilities to make biologics. We will learn from making biosimilars in the expectation that in the future we will develop [novel] biologics of our own."
Andrew Simpson, scientific director of Orygen Biologica Ltda, a joint venture of Brazilian pharmaceutical firms Eurofarma Laboratorios SA and Biolab Sanus Farmaceutica Ltda. on the Brazilian government promising to switch its current $1 billion per annum purchase of imported originator drugs to biologics that are manufactured in the country

"I believe that we will see a revolution in vaccines over the next decade."
Rino Rappuoli, chief scientist at Glaxosmithkline vaccines, at the International Conference on Antimicrobials and Chemotherapy and the International Congress of Chemotherapy annual meeting

"Regardless of who the Democratic nominee is, the party's platform will be in favor of drug pricing regulation, so none of this should be a surprise. However, there is almost no chance that a 2017 Democratic president . . . could successfully legislate drug pricing regulation."
Terry Haines, a Washington analyst, Evercore ISI

"We also need policies to have biosimilars competition development to be sustainable, and that includes an emphasis on quality so patients have confidence in those molecules."
Richard Markus, executive medical director for global biosimilars development at Amgen Inc., discussing development of the Avastin biosimilar ABP 215, partnered with Allergan plc